Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...
Cancer
Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia
Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA:...
Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...
Sino-Cuban JV Biotech Pharmaceutical Receives NMPA Approval for Nimotuzumab in Pancreatic Cancer
Sino-Cuban joint venture (JV) Biotech Pharmaceutical Limited (BPL) announced last week that it has received...
BeiGene Initiates First-in-Human Trial for Next-Generation BCL-2 Inhibitor BGB-21447
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the first patient dosing in...
Bio-Thera Solutions’ PD-1 Inhibitor BAT1308 Approved for Cervical Cancer Clinical Trials in China
Bio-Thera Solutions Ltd (SHA: 688177) has announced that its programmed death-1 (PD-1) inhibitor, BAT1308, has...
Medivir AB Receives Chinese Patent Approval for Liver Cancer Treatment Fostroxacitabine Bralpamide
Sweden-based Medivir AB (FRA: MVR0) has announced the approval of a patent in China for...
Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the...
United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million...
Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project
Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced...
Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial
China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug...
TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US...
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...
Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...
BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma
China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...
Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...
Takeda and HutchMed’s Elunate Study Results Published in The Lancet
Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...
CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...
Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors
China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...